In the long and humbling history of medicine's effort to conquer heart disease, another promising candidate has met the wall that separates early hope from clinical proof. A jointly developed experimental drug by Novartis and Ionis failed to achieve its primary efficacy endpoint in a closely watched trial, reminding investors, scientists, and patients alike that biological complexity rarely yields to expectation. The setback invites both companies to reckon with what the data truly says — and to decide, with honesty, what path forward serves the people medicine is ultimately meant to reach.